Pacira BioSciences (PCRX) Earnings Analysis

Pacira BioSciences (PCRX) has no confirmed upcoming earnings date. Last quarter (2026-04-30) it missed with EPS 0.6 USD vs 0.61 USD est (-1.6%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 209.58.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PCRX next report earnings?

No confirmed upcoming earnings date is currently scheduled for PCRX. This page updates as the calendar is published.

PCRX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-300.6 USD0.61 USD-1.6%Miss
2026-02-260.57 USD0.85 USD-32.9%Miss
2025-11-060.7 USD0.65 USD+7.7%Beat
2025-02-270.91 USD0.78 USD+16.7%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

PCRX valuation and analyst view

Trailing P/E209.58
Trailing EPS0.12699 USD
Price / book1.58
Dividend yield0.00%
Market cap1.00B
Analyst consensusHold (15 buy / 17 hold / 4 sell)
Avg price target32 USD

Related research pages

Frequently asked questions

When is Pacira BioSciences (PCRX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for PCRX. This page updates as the calendar is published.

Did PCRX beat earnings last quarter?

In its 2026-04-30 report, PCRX posted EPS of 0.6 USD versus a 0.61 USD estimate — a miss of 1.6%.

What is PCRX's earnings track record?

Over the last 4 reported quarters with consensus data, PCRX beat estimates 2 times (50%).

What is PCRX's current P/E ratio and EPS?

PCRX trades at a trailing P/E of 209.58 on trailing EPS of 0.12698648080867997 USD.

What do analysts rate PCRX?

Analyst consensus is "Hold" across 36 ratings (0 strong buy, 15 buy, 17 hold, 4 sell, 0 strong sell). Average 12-month price target: 32 USD.